CN1221546C - 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途 - Google Patents
二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途 Download PDFInfo
- Publication number
- CN1221546C CN1221546C CNB018210430A CN01821043A CN1221546C CN 1221546 C CN1221546 C CN 1221546C CN B018210430 A CNB018210430 A CN B018210430A CN 01821043 A CN01821043 A CN 01821043A CN 1221546 C CN1221546 C CN 1221546C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- phenyl
- pyridine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10064402A DE10064402A1 (de) | 2000-12-21 | 2000-12-21 | Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10064402.3 | 2000-12-21 | ||
DE10154518.5 | 2001-11-07 | ||
DE10154518 | 2001-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1481378A CN1481378A (zh) | 2004-03-10 |
CN1221546C true CN1221546C (zh) | 2005-10-05 |
Family
ID=26008044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018210430A Expired - Fee Related CN1221546C (zh) | 2000-12-21 | 2001-12-11 | 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途 |
Country Status (24)
Country | Link |
---|---|
US (1) | US6703386B2 (zh) |
EP (1) | EP1345924B1 (zh) |
JP (1) | JP2004516289A (zh) |
KR (1) | KR20030063462A (zh) |
CN (1) | CN1221546C (zh) |
AR (1) | AR033600A1 (zh) |
AT (1) | ATE338039T1 (zh) |
AU (1) | AU2002231688A1 (zh) |
BR (1) | BR0116322A (zh) |
CA (1) | CA2431995A1 (zh) |
CZ (1) | CZ20031733A3 (zh) |
DE (1) | DE50110906D1 (zh) |
EE (1) | EE200300238A (zh) |
HK (1) | HK1060119A1 (zh) |
HR (1) | HRP20030501A2 (zh) |
HU (1) | HUP0401073A2 (zh) |
IL (1) | IL156548A0 (zh) |
MX (1) | MXPA03005019A (zh) |
NO (1) | NO20032735L (zh) |
NZ (1) | NZ526594A (zh) |
PL (1) | PL362512A1 (zh) |
SK (1) | SK7782003A3 (zh) |
WO (1) | WO2002050060A1 (zh) |
YU (1) | YU47803A (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ309209B6 (cs) * | 2001-01-26 | 2022-05-25 | Schering Corporation | Farmaceutický prostředek |
JP2004517919A (ja) * | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ |
EP1671650A1 (en) * | 2001-01-26 | 2006-06-21 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
AU2002241956A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
EP1353694B1 (en) * | 2001-01-26 | 2007-12-19 | Schering Corporation | Combinations of ezetimibe with aspirine for treating vascular conditions |
TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
US7132415B2 (en) * | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
US7671047B2 (en) | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
DE10227508A1 (de) * | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US7176193B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
US7176194B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
DE10227507A1 (de) * | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
DE10303900A1 (de) * | 2003-01-31 | 2004-08-12 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend Levane |
ATE418551T1 (de) | 2003-03-07 | 2009-01-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
US20070161577A1 (en) * | 2003-08-28 | 2007-07-12 | Martinez Eduardo J | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
AU2004303742B2 (en) * | 2003-12-23 | 2008-06-19 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
DE102004024454A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
US7700597B2 (en) | 2004-12-03 | 2010-04-20 | Schering Corporation | Substituted piperazines as CB1 antagonists |
AU2006262441A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine H3 antagonists |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
KR20080097426A (ko) | 2006-01-18 | 2008-11-05 | 쉐링 코포레이션 | 칸나비노이드 수용체 조절제 |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
KR20100051625A (ko) * | 2007-06-28 | 2010-05-17 | 인터벳 인터내셔널 비.브이. | Cb1 길항제로서의 치환된 피페라진 |
CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2403848A1 (en) | 2009-03-06 | 2012-01-11 | Lipideon Biotechnology AG | Pharmaceutical hypocholesterolemic compositions |
CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
PL327938A1 (en) | 1996-01-17 | 1999-01-04 | Novo Nordisk As | Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application |
CA2264243C (en) | 1996-08-30 | 2004-10-05 | Novo Nordisk A/S | Glp-1 derivatives |
DE19845402B4 (de) * | 1998-10-02 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
PT869121E (pt) * | 1997-04-04 | 2004-10-29 | Aventis Pharma Gmbh | Derivados de propanolamina hipolipidemicos |
WO1999003861A1 (en) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
DE19845406C2 (de) * | 1998-10-02 | 2001-10-18 | Aventis Pharma Gmbh | Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
-
2001
- 2001-12-11 HU HU0401073A patent/HUP0401073A2/hu unknown
- 2001-12-11 CA CA002431995A patent/CA2431995A1/en not_active Abandoned
- 2001-12-11 BR BR0116322-1A patent/BR0116322A/pt not_active IP Right Cessation
- 2001-12-11 WO PCT/EP2001/014533 patent/WO2002050060A1/de not_active Application Discontinuation
- 2001-12-11 MX MXPA03005019A patent/MXPA03005019A/es active IP Right Grant
- 2001-12-11 EE EEP200300238A patent/EE200300238A/xx unknown
- 2001-12-11 YU YU47803A patent/YU47803A/sh unknown
- 2001-12-11 AT AT01991821T patent/ATE338039T1/de not_active IP Right Cessation
- 2001-12-11 KR KR10-2003-7008503A patent/KR20030063462A/ko not_active Application Discontinuation
- 2001-12-11 NZ NZ526594A patent/NZ526594A/en unknown
- 2001-12-11 JP JP2002551556A patent/JP2004516289A/ja not_active Abandoned
- 2001-12-11 EP EP01991821A patent/EP1345924B1/de not_active Expired - Lifetime
- 2001-12-11 DE DE50110906T patent/DE50110906D1/de not_active Expired - Lifetime
- 2001-12-11 CZ CZ20031733A patent/CZ20031733A3/cs unknown
- 2001-12-11 SK SK778-2003A patent/SK7782003A3/sk unknown
- 2001-12-11 IL IL15654801A patent/IL156548A0/xx unknown
- 2001-12-11 AU AU2002231688A patent/AU2002231688A1/en not_active Abandoned
- 2001-12-11 CN CNB018210430A patent/CN1221546C/zh not_active Expired - Fee Related
- 2001-12-11 PL PL01362512A patent/PL362512A1/xx not_active Application Discontinuation
- 2001-12-19 US US10/021,044 patent/US6703386B2/en not_active Expired - Lifetime
- 2001-12-19 AR ARP010105908A patent/AR033600A1/es unknown
-
2003
- 2003-06-16 NO NO20032735A patent/NO20032735L/no not_active Application Discontinuation
- 2003-06-18 HR HR20030501A patent/HRP20030501A2/xx not_active Application Discontinuation
-
2004
- 2004-04-22 HK HK04102853A patent/HK1060119A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20020128253A1 (en) | 2002-09-12 |
SK7782003A3 (en) | 2003-12-02 |
EE200300238A (et) | 2003-08-15 |
NZ526594A (en) | 2004-08-27 |
CN1481378A (zh) | 2004-03-10 |
PL362512A1 (en) | 2004-11-02 |
HRP20030501A2 (en) | 2005-04-30 |
ATE338039T1 (de) | 2006-09-15 |
BR0116322A (pt) | 2003-10-14 |
EP1345924B1 (de) | 2006-08-30 |
AU2002231688A1 (en) | 2002-07-01 |
US6703386B2 (en) | 2004-03-09 |
NO20032735L (no) | 2003-08-06 |
CZ20031733A3 (cs) | 2003-09-17 |
AR033600A1 (es) | 2003-12-26 |
JP2004516289A (ja) | 2004-06-03 |
WO2002050060A1 (de) | 2002-06-27 |
YU47803A (sh) | 2006-05-25 |
CA2431995A1 (en) | 2002-06-27 |
HK1060119A1 (en) | 2004-07-30 |
KR20030063462A (ko) | 2003-07-28 |
MXPA03005019A (es) | 2003-09-25 |
DE50110906D1 (de) | 2006-10-12 |
IL156548A0 (en) | 2004-01-04 |
HUP0401073A2 (hu) | 2004-09-28 |
EP1345924A1 (de) | 2003-09-24 |
NO20032735D0 (no) | 2003-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1221546C (zh) | 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途 | |
CN1481381A (zh) | 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途 | |
CN1662494A (zh) | 阳离子取代的二苯基2-吖丁啶酮、它们的制备方法、含有所述化合物的药物及其用途 | |
CN100467448C (zh) | 被酸性基团取代的二苯基氮杂环丁酮、其制备方法、含有它们的药物及其用途 | |
CN1286805C (zh) | 酰基-4-羧基苯基脲衍生物、其制备方法及用途 | |
CN1144522A (zh) | 用作降低血胆固醇药物的取代氮杂环丁酮化合物 | |
CN1176080C (zh) | 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途 | |
US7388004B2 (en) | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | |
CN1768034A (zh) | 具有改善的生理学性质的新的二苯基2-吖丁啶酮、其制备方法、包含所述化合物的药物和所述化合物的用途 | |
CN88102247A (zh) | 新颖的吡唑并[3,4-d]嘧啶、其制备方法及其药物组合物 | |
CN1659137A (zh) | N-苯甲酰基脲基肉桂酸衍生物、其制备方法及其用途 | |
CN1150950A (zh) | 头孢菌素衍生物 | |
US7671047B2 (en) | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | |
CN1759109A (zh) | 取代的苯甲酰基脲基吡啶基-哌啶-和-吡咯烷甲酸衍生物,它们的制备方法和用途 | |
RU2282628C2 (ru) | Производные дифенилазетидинона, фармацевтическая композиция на их основе и способ ее получения | |
NZ537302A (en) | Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof | |
NZ537303A (en) | Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060119 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SANOFI- AVENTIS GERMAN CO., LTD. Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Frankfurt, Germany Patentee after: Hoechst Marion Roussel de GmbH Address before: Frankfurt, Germany Patentee before: Awentis Medicines Deutschland GmbH |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |